BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

17 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones

09 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219

04 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

14 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

12 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference

11 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights

07 Nov 2022 15:27:31 By Nasdaq GlobeNewswire

Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting

03 Nov 2022 08:19:37 By Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

31 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

BMF-219 Enters the Clinic for KRAS Solid Tumors

14 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

22 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

20 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

26 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

01 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

01 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

22 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

04 Jun 2022 10:00:00 By Nasdaq GlobeNewswire

Biomea Fusion to Participate in Jefferies Healthcare Conference

02 Jun 2022 17:00:00 By Nasdaq GlobeNewswire

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022

01 Jun 2022 07:30:00 By Nasdaq GlobeNewswire